| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GFAP; FLJ45472; cb345; ALXDRD |
| Entrez GeneID | 2670 |
| WB Predicted band size | Calculated MW: 50 kDa; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human GFAP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于GFAP抗体的3篇参考文献及其摘要概括：
1. **《Monoclonal antibodies to glial fibrillary acidic protein (GFAP) in the study of astrocytic tumors**
- 作者：Eng, L. F., & Ghirnikar, R. S.
- 摘要：该研究利用GFAP单克隆抗体，分析了星形细胞瘤等神经胶质瘤中GFAP的表达模式，证实其作为星形胶质细胞特异性标志物在肿瘤病理诊断中的价值。
2. **《GFAP and astrogliosis**
- 作者：Brenner, M.
- 摘要：探讨GFAP在神经损伤和疾病(如阿尔茨海默病、多发性硬化)中的表达变化，强调其作为胶质细胞活化的关键指标，并讨论抗体在检测神经炎症中的应用。
3. **《Astrocyte markers in neurological diseases: GFAP as a potential biomarker**
- 作者：Middeldorp, J., & Hol, E. M.
- 摘要：综述GFAP抗体在脑脊液和血液检测中的进展，提出GFAP作为神经退行性疾病(如ALS、脑损伤)的生物学标志物，及其在疾病监测中的意义。
Glial fibrillary acidic protein (GFAP) antibodies target GFAP, an intermediate filament protein predominantly expressed in astrocytes of the central nervous system (CNS). First identified in the 1970s, GFAP is a key marker for astrocytes, playing roles in maintaining structural integrity, cell signaling, and response to CNS injury. Antibodies against GFAP are widely used in research and diagnostics to visualize astrocytes and assess their reactivity in neurological conditions, including neuroinflammation, traumatic brain injury, neurodegenerative diseases (e.g., Alzheimer’s), and brain tumors (e.g., gliomas).
In clinical pathology, GFAP immunohistochemistry helps distinguish astrocytic tumors from other CNS neoplasms. Autoantibodies against GFAP, identified in cerebrospinal fluid (CSF) or serum, are linked to autoimmune GFAP astrocytopathy, a treatable inflammatory disorder presenting with meningoencephalitis, myelitis, or optic neuropathy. Detection methods (e.g., immunohistochemistry, Western blot, ELISA) vary by application, with CSF analysis increasingly used to monitor disease activity.
Recent studies explore GFAP isoforms and post-translational modifications, revealing subtype-specific roles in astrocyte heterogeneity and disease mechanisms. GFAP remains a critical tool for understanding astrocyte biology and CNS pathology, bridging basic research and clinical diagnostics.
×
